About this trial
The Correlation between hs CRP TG triglycerides Glucose index in NAFLD and liver fibrosis
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults ≥18 years
Available fasting labs: TG, fasting glucose, hs-CRP
Valid liver assessment by VCTE (FibroScan LSM) and CAP or ultrasound-based steatosis assessment
Disqualifiers
1- Significant alcohol intake (define using your local standard; commonly sex-specific thresholds) 2- Viral hepatitis (HBsAg positive and/or HCV RNA positive) 3- Other chronic liver diseases (autoimmune hepatitis, hemochromatosis, Wilson's, etc.) 4- Pregnancy
Trial population
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent chronic liver disease in the world, affecting one-fourth of the global population, and represents a serious public health issue. NAFLD encompasses a broad spectrum of liver abnormalities, ranging from simple hepatic steatosis, which is thought to be benign, to non-Alcoholic Steatohepatitis (NASH) without fibrosis and progressing to fibrotic NASH. The evolution of liver fibrosis results in irreversible architectural changes of the liver and can progress to Hepatocellular Carcinoma (HCC) (Sheka et al., 2020; Zhou et al., 2025). NAFLD is associated with an increased risk of systemic metabolic disorders, such as hyperuricemia, hyperlipidemia, IR, and hyperglycemia. These metabolic disorders, in combination with NAFLD, contribute to the risk of developing extrahepatic malignancies and cardiovascular diseases, which are the main causes of extrahepatic mortality (Li et al., 2022). High-sensitivity C-reactive protein
Trial design
Other
Cross-sectional
Treatments tested in this trial
• Fasting triglycerides (TG) • Fasting plasma glucose • High-sensitivity C-reactive protein (hs-CRP) • Liver enzymes (ALT, AST, GGT) • Platelet count • HbA1c • Lipid profile (total cholesterol, HDL-C,
Other interventionParticipants will be instructed to fast for 8-12 hours before blood sampling. Venous blood samples will be collected in the morning and analyzed in a certified laboratory for: * Fasting triglycerides (TG) * Fasting plasma glucose * High-sensitivity C-reactive protein (hs-CRP) * Liver enzymes (ALT, AST, GGT) * Platelet count * HbA1c * Lipid profile (total cholesterol, HDL-C, LDL-C)
Treatment groups
Trial outcomes
Primary outcomes
Presence of NAFLD (defined by CAP ≥248 dB/m after exclusion of secondary causes).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: